RxDoctor Payments Data

George Tadros, MD

Interventional Cardiology · Laguna Hills, CANPI 1588623144

Payments from drug & device makers

$11,184in general payments, 2019–2025

Across 123 payments — averaging $90.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$4K
  • Edwards Lifesciences$659
  • Inari Medical, Inc.$509
  • Shockwave Medical, Inc$418
  • Heartflow, Inc.$203
  • plus $843 from 13 others

What the payments were for

  • Consulting fees$1,50020%
  • Travel & lodging$2593%
  • Food & beverage$5,76176%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,184 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$93,079
Medicare patients
1,142
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$125,941
Repatha SureclickEvolocumab59$74,655
XareltoRivaroxaban28$36,431
Praluent PenAlirocumab16$14,406
Metoprolol Succinate254$5,837
Rosuvastatin Calcium132$2,274
ClopidogrelClopidogrel Bisulfate128$1,912
Isosorbide Mononitrate ErIsosorbide Mononitrate84$1,686
Atorvastatin Calcium109$1,535
Amlodipine Besylate78$1,066
Metoprolol Tartrate100$934
Lisinopril66$809
Torsemide21$659
Losartan Potassium53$641
Spironolactone31$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$125,94188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →